Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax, Zanubrutinib and Obinutuzumab in First-Line High-Risk Mantle Cell Lymphoma
NCT07548255Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonrotoclax and zanubrutinib in mantle cell lymphoma (MCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate at 24 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07548255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548255.